Clinical Trial: PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR
Brief Summary: The purpose of this protocol is to measure peripheral benzodiazepine receptors in the brain using positron emission tomography (PET) and compare the imaging results between patients and healthy people.
Detailed Summary:
Objective
In endemic regions neurocysticercosis is the most common cause of adult acquired epilepsy and thus an important public health problem. The disease is caused by infection with the larval form of the tapeworm, Taenia solium. Although neurocysticercosis is common only in many developing regions, an increased number of patients are diagnosed in developed countries mostly due to immigration of infected individuals.
The peripheral benzodiazepine receptor (PBR) can be a clinically useful marker to detect neuroinflammation because activated microglia in inflammatory areas expresses high levels of PBR. PBR has been imaged with positron emission tomography (PET) using [(11) C]1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline carboxamide (PK11195), which provides low levels of specific signal. Recently we developed a new ligand, N-fluroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline ([(18)F]FBR), which showed much greater specific signals than [(11) C]PK11195 in non-human primates.
The major objective of this protocol is to assess the utility of [(18) F]FBR PET to detect neuroinflammation in patients with neurocysticercosis.
A secondary objective is to study whether some healthy subjects do not show binding of [(18)F]FBR by performing whole body imaging using [18F]FBR and binding assays using blood cells. In other protocols using a PET ligand with similar structure, [(11)C]PBR28, approximately 8% of subjects (9/~ 118 ) did not show binding. In protocols 07-N-0035 and 08-M-0158, we compared binding of [11C]PBR28 and [(11)C]PK 11195 in approximately ten healthy subjects including five who did not show binding of [(11)C]PBR28 in prior whole body imaging. We found differences in organs with regard to sensitivity to the phenomenon
Sponsor: National Institute of Mental Health (NIMH)
Current Primary Outcome: Binding of [F-18]FBR at peripheral benzodiazepine receptor. [ Time Frame: 3 years ]
Original Primary Outcome: Binding of [F-18]FBR at peripheral benzodiazepine receptor.
Current Secondary Outcome: MRI [ Time Frame: 3 years ]
Original Secondary Outcome:
Information By: National Institutes of Health Clinical Center (CC)
Dates:
Date Received: September 8, 2007
Date Started: September 4, 2007
Date Completion:
Last Updated: May 12, 2017
Last Verified: November 26, 2013
